| Wed, Feb 03, 2010 |
|
Earnings Preview: Boston Scientific Corporation (NYSE:BSX)
Boston Scientific Corporation is scheduled to report December 2009 quarter (Q4 2009) results on Wednesday, February 10, 2010. In the last four quarters ending September 2009, the company disappointed investors with below analysts’ consensus estimates. [More...]
-
home: iStockAnalyst....
|
| Mon, Feb 01, 2010 |
|
(AMMD) American Medical Systems Holdings Earns New Agreement
American Medical Systems Holdings, Inc. (AMMD) recently entered into a new agreement with Tissue Genesis, Inc., an emerging leader in advanced tissue engineering and cell therapy solutions, for the research and development of adipose (fat) derived regenerative cells for use in treating pelvic health disorders.
Per the agreement, American Medical has a four year option to [...]
(AMMD) American Medical Systems Holdings Earns New Agreement
-
Stock Blog Hub
|
|
(MDRX) Medical Devices Stock Review – Feburary 2010 – Industry Outlook
The global medical devices industry is fairly large, with annual worldwide sales in excess of $200 billion. The U.S. accounts for approximately 41% of this market. The industry is divided into different categories such as Cardiology, Oncology, Neuro, Orthopedic, Aesthetic Devices, Healthcare IT, etc.
We recommend companies providing life-sustaining products to investors in the medical devices [...]
(MDRX) Medical Devices Stock Review – Feburary 2010 – Industry Outlook
-
Stock Blog Hub
|
|
Boston Scientific: Must Pay JNJ To Settle Patent Dispute
A patent dispute regarding Boston Scientific (BSX) cardiac stents dating back to 2003 has finally come to a close with Boston Scientific to pay Johnson & Johnson (JNJ) $1.725 billion in two tranches. This major settlement is in addition to a separate patent settlement last September in which BSX must pay $716 million to JNJ. [More...]
-
home: iStockAnalyst....
|
|
New Agreement For AMMD
American Medical Systems Holdings, Inc. (AMMD) recently entered into a new agreement with Tissue Genesis, Inc., an emerging leader in advanced tissue engineering and cell therapy solutions, for the research and development of adipose (fat) derived regenerative cells for use in treating pelvic health disorders.
Per the agreement, American Medical has a four year option to ...
-
Daily Markets
|
|
More Blogs
|